Follow
'Decreased access to biomarker testing can result in delays of appropriate treatment, poor outcomes related to use of ineffective treatment and lack of access to clinical trials with biomarker-based entry criteria. Thus, the opportunities to receive benefits of precision oncology are most realized in high-income, urban and academic settings.'
